This years North American Cystic Fibrosis Conference (NACFC), will be held in Orlando from October 27th through the 29th. Below are some abstracts to look for during that conference.
Concert: Abstract 224: CTP-656 Multiple Dose Pharmacokinetic Profile Continues to Support a Once-Daily Potentiator for Cystic Fibrosis Patients with Gating Mutations. The trial showed a superior PK profile compared to ivacaftor.
Galapagos: Abstract 252: Safety, tolerability, and pharmacokinetics of a novel CFTR corrector molecule GLPG2222 in healthy volunteers. Full safety and PK data will be presented at the conference.
Galapagos: Abstract 253: GLPG1837 in subjects with cystic fibrosis (CF) and the S1251N mutation: Results from a phase IIA study (SAPHIRA2). Pending results September.
Proteostasis Therapeutics: Abstract 187: Phase 1 initial results evaluating safety, tolerability, PK and biomarker data using PTI-428, a novel CFTR modulator, in patients with cystic fibrosis. PTI-428 is an amplifier designed for any mutation.
Vertex: Abstract 188: Discovery and biological profile of next-generation CFTR Correctors. VX-152 and VX-440 are highlighted in this abstract. Vertex has other abstracts listed, that have been previously presented.
The link to the NACFC abstracts can be found here, 2016 NACFC Abstracts.
Thank you for reading.
Concert: Abstract 224: CTP-656 Multiple Dose Pharmacokinetic Profile Continues to Support a Once-Daily Potentiator for Cystic Fibrosis Patients with Gating Mutations. The trial showed a superior PK profile compared to ivacaftor.
Galapagos: Abstract 252: Safety, tolerability, and pharmacokinetics of a novel CFTR corrector molecule GLPG2222 in healthy volunteers. Full safety and PK data will be presented at the conference.
Galapagos: Abstract 253: GLPG1837 in subjects with cystic fibrosis (CF) and the S1251N mutation: Results from a phase IIA study (SAPHIRA2). Pending results September.
Proteostasis Therapeutics: Abstract 187: Phase 1 initial results evaluating safety, tolerability, PK and biomarker data using PTI-428, a novel CFTR modulator, in patients with cystic fibrosis. PTI-428 is an amplifier designed for any mutation.
Vertex: Abstract 188: Discovery and biological profile of next-generation CFTR Correctors. VX-152 and VX-440 are highlighted in this abstract. Vertex has other abstracts listed, that have been previously presented.
The link to the NACFC abstracts can be found here, 2016 NACFC Abstracts.
Thank you for reading.
No comments:
Post a Comment